Will newly-joined domestic pharmaceutical companies be successful in DPP-4 diabetic treatment market?
The DPP-4 inhibitor diabetes treatment market, which has been occupied by Januvia and Trajenta, has recently been invaded by domestic pharmaceutical companies.
Handok has made progress in commercializing ambitiously prepared ‘Tenelia,’ a single drug, after the end of the Galvus’s sales license, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
